Efficient Identification of High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method
* Context.--The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited a surge in demand for serologic testing to identify previously infected individuals. In particular, antibody testing is crucial in identifying COVID-19 convalescent plasm...
Gespeichert in:
| Veröffentlicht in: | Archives of pathology & laboratory medicine (1976) 2021-10, Vol.145 (10), p.1221-1227 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1227 |
|---|---|
| container_issue | 10 |
| container_start_page | 1221 |
| container_title | Archives of pathology & laboratory medicine (1976) |
| container_volume | 145 |
| creator | Nguyen, Khoa D. Wirz, Oliver F. Röltgen, Katharina Pandey, Suchitra Tolentino, Lorna Boyd, Scott D. Pham, Tho D. |
| description | * Context.--The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited a surge in demand for serologic testing to identify previously infected individuals. In particular, antibody testing is crucial in identifying COVID-19 convalescent plasma, which has been approved by the Food and Drug Administration under the Emergency Use Authorization for use as passive immunotherapy for hospitalized patients infected with COVID-19. Currently, high-titer COVID-19 convalescent plasma can be qualified by Ortho's Vitros COVID-19 IgG antibody test. Objective.--To explore the use of an efficient testing method to identify high-titer COVID-19 convalescent plasma for use in treating COVID-19-infected patients and track COVID-19 positivity over time. Design.--We evaluated an enzyme-linked immunosorbent assay (ELISA)-based method that detects antibodies specific to the SARS-CoV-2 receptor binding domain (RBD) with individual and pooled plasma samples and compared its performance against the Vitros COVID-19 IgG antibody test. Using the pooled RBD-ELISA (P-RE) method, we also screened more than 10 000 longitudinal healthy blood donor samples to assess seroprevalence. Results.--P-RE demonstrates 100% sensitivity in detecting Food and Drug Administration-defined high-titer samples when compared with the Vitros COVID-19 IgG antibody test. Overall sensitivity of P-RE when compared with the Vitros COVID-19 IgG antibody test and our individual sample RBD-ELISA (I-RE) were 83% and 56%, respectively. When screening 10 218 healthy blood donor samples by P-RE, we found the seroprevalence correlated with the local infection rates with a correlation coefficient of 0.21 (P < .001). Conclusions.--Pooling plasma samples can be used to efficiently screen large populations for individuals with high-titer anti-RBD antibodies, important for COVID-19 convalescent plasma identification. doi: 10.5858/arpa.2021-0215-SA |
| doi_str_mv | 10.5858/arpa.2021-0215-SA |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2539527526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A680117878</galeid><sourcerecordid>A680117878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-e4270687bbc57c787f0d50a8adb5844824048b08df1fb19da884cb24f75ecfe63</originalsourceid><addsrcrecordid>eNpdkc9u1DAQxiMEEkvhAbhZQkLl4GI79to5RquWVioCNYWr5TjjXVdJHGyn0t54B3hCnoSEIvHnMDOamZ8-jeYripeUnAkl1FsTJ3PGCKN4CYGb-lGxoYKXmNGteFxsCCElriolnhbPUrpb2ooxuim-nzvnrYcxo6tuyX7pTPZhRMGhS78_4FufIaJ6Wf34-q2Be4iAajtnQDeQJh9NDvGImuPYxTAA2oUYRnPv45wQQ6dNfdPgXfiM2ZtfGm3ojuhjb9JgUGOGqYeE2mUSQu_HPXoP-RC658UTZ_oEL37Xk-LTxfnt7hJff3h3tauvsS2pzBg4k2SrZNtaIa1U0pFOEKNM1wrFuWKccNUS1TnqWlp1RiluW8adFGAdbMuT4vRBd4rhywwp68EnC31vRghz0kyUlWBSsBV99R96F-Y4LtctlKwop4qpP9Te9KD96EKOxq6iut4qQuly5Eq9_os6gOnzIYV-Xt-e_gXpA2hjSCmC01P0g4lHTYlebder7Xq1Xa-266YufwJOQqDC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579141828</pqid></control><display><type>article</type><title>Efficient Identification of High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method</title><source>Allen Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Nguyen, Khoa D. ; Wirz, Oliver F. ; Röltgen, Katharina ; Pandey, Suchitra ; Tolentino, Lorna ; Boyd, Scott D. ; Pham, Tho D.</creator><creatorcontrib>Nguyen, Khoa D. ; Wirz, Oliver F. ; Röltgen, Katharina ; Pandey, Suchitra ; Tolentino, Lorna ; Boyd, Scott D. ; Pham, Tho D.</creatorcontrib><description>* Context.--The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited a surge in demand for serologic testing to identify previously infected individuals. In particular, antibody testing is crucial in identifying COVID-19 convalescent plasma, which has been approved by the Food and Drug Administration under the Emergency Use Authorization for use as passive immunotherapy for hospitalized patients infected with COVID-19. Currently, high-titer COVID-19 convalescent plasma can be qualified by Ortho's Vitros COVID-19 IgG antibody test. Objective.--To explore the use of an efficient testing method to identify high-titer COVID-19 convalescent plasma for use in treating COVID-19-infected patients and track COVID-19 positivity over time. Design.--We evaluated an enzyme-linked immunosorbent assay (ELISA)-based method that detects antibodies specific to the SARS-CoV-2 receptor binding domain (RBD) with individual and pooled plasma samples and compared its performance against the Vitros COVID-19 IgG antibody test. Using the pooled RBD-ELISA (P-RE) method, we also screened more than 10 000 longitudinal healthy blood donor samples to assess seroprevalence. Results.--P-RE demonstrates 100% sensitivity in detecting Food and Drug Administration-defined high-titer samples when compared with the Vitros COVID-19 IgG antibody test. Overall sensitivity of P-RE when compared with the Vitros COVID-19 IgG antibody test and our individual sample RBD-ELISA (I-RE) were 83% and 56%, respectively. When screening 10 218 healthy blood donor samples by P-RE, we found the seroprevalence correlated with the local infection rates with a correlation coefficient of 0.21 (P < .001). Conclusions.--Pooling plasma samples can be used to efficiently screen large populations for individuals with high-titer anti-RBD antibodies, important for COVID-19 convalescent plasma identification. doi: 10.5858/arpa.2021-0215-SA</description><identifier>ISSN: 0003-9985</identifier><identifier>ISSN: 1543-2165</identifier><identifier>EISSN: 1543-2165</identifier><identifier>DOI: 10.5858/arpa.2021-0215-SA</identifier><language>eng</language><publisher>Northfield: College of American Pathologists</publisher><subject>ACE2 ; Angiotensin ; Angiotensin-converting enzyme 2 ; Antibodies ; Blood & organ donations ; Blood plasma ; Clinical trials ; Coronaviruses ; COVID-19 ; Dexamethasone ; Enzyme-linked immunosorbent assay ; Enzymes ; FDA approval ; Health care ; Hospitalization ; Hygiene ; Immune system ; Immunoglobulin G ; Mechanical ventilation ; Monoclonal antibodies ; Mortality ; Pandemics ; Patients ; Peptidyl-dipeptidase A ; Plasma ; Population studies ; Proteins ; Public health ; Respiratory tract ; Severe acute respiratory syndrome coronavirus 2 ; Testing ; Vaccines</subject><ispartof>Archives of pathology & laboratory medicine (1976), 2021-10, Vol.145 (10), p.1221-1227</ispartof><rights>COPYRIGHT 2021 College of American Pathologists</rights><rights>Copyright College of American Pathologists Oct 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c317t-e4270687bbc57c787f0d50a8adb5844824048b08df1fb19da884cb24f75ecfe63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Nguyen, Khoa D.</creatorcontrib><creatorcontrib>Wirz, Oliver F.</creatorcontrib><creatorcontrib>Röltgen, Katharina</creatorcontrib><creatorcontrib>Pandey, Suchitra</creatorcontrib><creatorcontrib>Tolentino, Lorna</creatorcontrib><creatorcontrib>Boyd, Scott D.</creatorcontrib><creatorcontrib>Pham, Tho D.</creatorcontrib><title>Efficient Identification of High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method</title><title>Archives of pathology & laboratory medicine (1976)</title><description>* Context.--The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited a surge in demand for serologic testing to identify previously infected individuals. In particular, antibody testing is crucial in identifying COVID-19 convalescent plasma, which has been approved by the Food and Drug Administration under the Emergency Use Authorization for use as passive immunotherapy for hospitalized patients infected with COVID-19. Currently, high-titer COVID-19 convalescent plasma can be qualified by Ortho's Vitros COVID-19 IgG antibody test. Objective.--To explore the use of an efficient testing method to identify high-titer COVID-19 convalescent plasma for use in treating COVID-19-infected patients and track COVID-19 positivity over time. Design.--We evaluated an enzyme-linked immunosorbent assay (ELISA)-based method that detects antibodies specific to the SARS-CoV-2 receptor binding domain (RBD) with individual and pooled plasma samples and compared its performance against the Vitros COVID-19 IgG antibody test. Using the pooled RBD-ELISA (P-RE) method, we also screened more than 10 000 longitudinal healthy blood donor samples to assess seroprevalence. Results.--P-RE demonstrates 100% sensitivity in detecting Food and Drug Administration-defined high-titer samples when compared with the Vitros COVID-19 IgG antibody test. Overall sensitivity of P-RE when compared with the Vitros COVID-19 IgG antibody test and our individual sample RBD-ELISA (I-RE) were 83% and 56%, respectively. When screening 10 218 healthy blood donor samples by P-RE, we found the seroprevalence correlated with the local infection rates with a correlation coefficient of 0.21 (P < .001). Conclusions.--Pooling plasma samples can be used to efficiently screen large populations for individuals with high-titer anti-RBD antibodies, important for COVID-19 convalescent plasma identification. doi: 10.5858/arpa.2021-0215-SA</description><subject>ACE2</subject><subject>Angiotensin</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Antibodies</subject><subject>Blood & organ donations</subject><subject>Blood plasma</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Dexamethasone</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>FDA approval</subject><subject>Health care</subject><subject>Hospitalization</subject><subject>Hygiene</subject><subject>Immune system</subject><subject>Immunoglobulin G</subject><subject>Mechanical ventilation</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Peptidyl-dipeptidase A</subject><subject>Plasma</subject><subject>Population studies</subject><subject>Proteins</subject><subject>Public health</subject><subject>Respiratory tract</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Testing</subject><subject>Vaccines</subject><issn>0003-9985</issn><issn>1543-2165</issn><issn>1543-2165</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkc9u1DAQxiMEEkvhAbhZQkLl4GI79to5RquWVioCNYWr5TjjXVdJHGyn0t54B3hCnoSEIvHnMDOamZ8-jeYripeUnAkl1FsTJ3PGCKN4CYGb-lGxoYKXmNGteFxsCCElriolnhbPUrpb2ooxuim-nzvnrYcxo6tuyX7pTPZhRMGhS78_4FufIaJ6Wf34-q2Be4iAajtnQDeQJh9NDvGImuPYxTAA2oUYRnPv45wQQ6dNfdPgXfiM2ZtfGm3ojuhjb9JgUGOGqYeE2mUSQu_HPXoP-RC658UTZ_oEL37Xk-LTxfnt7hJff3h3tauvsS2pzBg4k2SrZNtaIa1U0pFOEKNM1wrFuWKccNUS1TnqWlp1RiluW8adFGAdbMuT4vRBd4rhywwp68EnC31vRghz0kyUlWBSsBV99R96F-Y4LtctlKwop4qpP9Te9KD96EKOxq6iut4qQuly5Eq9_os6gOnzIYV-Xt-e_gXpA2hjSCmC01P0g4lHTYlebder7Xq1Xa-266YufwJOQqDC</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Nguyen, Khoa D.</creator><creator>Wirz, Oliver F.</creator><creator>Röltgen, Katharina</creator><creator>Pandey, Suchitra</creator><creator>Tolentino, Lorna</creator><creator>Boyd, Scott D.</creator><creator>Pham, Tho D.</creator><general>College of American Pathologists</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20211001</creationdate><title>Efficient Identification of High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method</title><author>Nguyen, Khoa D. ; Wirz, Oliver F. ; Röltgen, Katharina ; Pandey, Suchitra ; Tolentino, Lorna ; Boyd, Scott D. ; Pham, Tho D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-e4270687bbc57c787f0d50a8adb5844824048b08df1fb19da884cb24f75ecfe63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACE2</topic><topic>Angiotensin</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Antibodies</topic><topic>Blood & organ donations</topic><topic>Blood plasma</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Dexamethasone</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>FDA approval</topic><topic>Health care</topic><topic>Hospitalization</topic><topic>Hygiene</topic><topic>Immune system</topic><topic>Immunoglobulin G</topic><topic>Mechanical ventilation</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Peptidyl-dipeptidase A</topic><topic>Plasma</topic><topic>Population studies</topic><topic>Proteins</topic><topic>Public health</topic><topic>Respiratory tract</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Testing</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Khoa D.</creatorcontrib><creatorcontrib>Wirz, Oliver F.</creatorcontrib><creatorcontrib>Röltgen, Katharina</creatorcontrib><creatorcontrib>Pandey, Suchitra</creatorcontrib><creatorcontrib>Tolentino, Lorna</creatorcontrib><creatorcontrib>Boyd, Scott D.</creatorcontrib><creatorcontrib>Pham, Tho D.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of pathology & laboratory medicine (1976)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Khoa D.</au><au>Wirz, Oliver F.</au><au>Röltgen, Katharina</au><au>Pandey, Suchitra</au><au>Tolentino, Lorna</au><au>Boyd, Scott D.</au><au>Pham, Tho D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficient Identification of High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method</atitle><jtitle>Archives of pathology & laboratory medicine (1976)</jtitle><date>2021-10-01</date><risdate>2021</risdate><volume>145</volume><issue>10</issue><spage>1221</spage><epage>1227</epage><pages>1221-1227</pages><issn>0003-9985</issn><issn>1543-2165</issn><eissn>1543-2165</eissn><abstract>* Context.--The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited a surge in demand for serologic testing to identify previously infected individuals. In particular, antibody testing is crucial in identifying COVID-19 convalescent plasma, which has been approved by the Food and Drug Administration under the Emergency Use Authorization for use as passive immunotherapy for hospitalized patients infected with COVID-19. Currently, high-titer COVID-19 convalescent plasma can be qualified by Ortho's Vitros COVID-19 IgG antibody test. Objective.--To explore the use of an efficient testing method to identify high-titer COVID-19 convalescent plasma for use in treating COVID-19-infected patients and track COVID-19 positivity over time. Design.--We evaluated an enzyme-linked immunosorbent assay (ELISA)-based method that detects antibodies specific to the SARS-CoV-2 receptor binding domain (RBD) with individual and pooled plasma samples and compared its performance against the Vitros COVID-19 IgG antibody test. Using the pooled RBD-ELISA (P-RE) method, we also screened more than 10 000 longitudinal healthy blood donor samples to assess seroprevalence. Results.--P-RE demonstrates 100% sensitivity in detecting Food and Drug Administration-defined high-titer samples when compared with the Vitros COVID-19 IgG antibody test. Overall sensitivity of P-RE when compared with the Vitros COVID-19 IgG antibody test and our individual sample RBD-ELISA (I-RE) were 83% and 56%, respectively. When screening 10 218 healthy blood donor samples by P-RE, we found the seroprevalence correlated with the local infection rates with a correlation coefficient of 0.21 (P < .001). Conclusions.--Pooling plasma samples can be used to efficiently screen large populations for individuals with high-titer anti-RBD antibodies, important for COVID-19 convalescent plasma identification. doi: 10.5858/arpa.2021-0215-SA</abstract><cop>Northfield</cop><pub>College of American Pathologists</pub><doi>10.5858/arpa.2021-0215-SA</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9985 |
| ispartof | Archives of pathology & laboratory medicine (1976), 2021-10, Vol.145 (10), p.1221-1227 |
| issn | 0003-9985 1543-2165 1543-2165 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2539527526 |
| source | Allen Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | ACE2 Angiotensin Angiotensin-converting enzyme 2 Antibodies Blood & organ donations Blood plasma Clinical trials Coronaviruses COVID-19 Dexamethasone Enzyme-linked immunosorbent assay Enzymes FDA approval Health care Hospitalization Hygiene Immune system Immunoglobulin G Mechanical ventilation Monoclonal antibodies Mortality Pandemics Patients Peptidyl-dipeptidase A Plasma Population studies Proteins Public health Respiratory tract Severe acute respiratory syndrome coronavirus 2 Testing Vaccines |
| title | Efficient Identification of High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A53%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficient%20Identification%20of%20High-Titer%20Anti%E2%80%93Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20(SARS-CoV-2)%20Antibody%20Plasma%20Samples%20by%20Pooling%20Method&rft.jtitle=Archives%20of%20pathology%20&%20laboratory%20medicine%20(1976)&rft.au=Nguyen,%20Khoa%20D.&rft.date=2021-10-01&rft.volume=145&rft.issue=10&rft.spage=1221&rft.epage=1227&rft.pages=1221-1227&rft.issn=0003-9985&rft.eissn=1543-2165&rft_id=info:doi/10.5858/arpa.2021-0215-SA&rft_dat=%3Cgale_proqu%3EA680117878%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579141828&rft_id=info:pmid/&rft_galeid=A680117878&rfr_iscdi=true |